Fezf2 promotes neuronal differentiation through localised activation of Wnt/β-catenin signalling during forebrain development

Siwei Zhang1,*, Jingjing Li1,‡, Robert Lea1, Kris Vleminckx2 and Enrique Amaya1,§

ABSTRACT

Brain regionalisation, neuronal subtype diversification and circuit connectivity are crucial events in the establishment of higher cognitive functions. Here we report the requirement for the transcriptional repressor Fezf2 for proper differentiation of neural progenitor cells during the development of the Xenopus forebrain. Depletion of Fezf2 induces apoptosis in postmitotic neural progenitors, with concomitant reduction in forebrain size and neuronal differentiation. Mechanistically, we found that Fezf2 stimulates neuronal differentiation by promoting Wnt/β-catenin signalling in the developing forebrain. In addition, we show that Fezf2 promotes activation of Wnt/β-catenin signalling by repressing the expression of two negative regulators of Wnt signalling, namely hfx2 and hfx9. Our findings suggest that Fezf2 plays an essential role in controlling when and where neuronal differentiation occurs within the developing forebrain and that it does so by promoting local Wnt/β-catenin signalling via a double-repressor model.

KEY WORDS: Fezf2, Wnt signalling, Xenopus, Forebrain development

INTRODUCTION

The vertebrate forebrain, which carries out higher neural functions, is a highly organised and complex structure derived from the anteriormost region of the neural plate. Although the extent of elaboration and the size of the various subdomains of the anterior central nervous system vary between species, the molecular mechanisms that generate the brain, including the patterning of the different forebrain subdomains and subsequent neuronal differentiation within each compartment, are highly conserved amongst vertebrates. Therefore, studies on the early development of the forebrain in zebrafish, frog, chick and mouse embryos have shed light on the conserved developmental programmes that contribute to the formation and development of the vertebrate brain (Wilson and Houart, 2004).

Forebrain development comprises three distinct stages. The first stage is neural induction during gastrulation, which defines both the position and identity of the anterior neuroectoderm. This stage is quickly followed by a second, patterning stage, whereby the anterior neuroectoderm is regionalised into the various forebrain subdomains by means of both transcriptional regulation and signal transduction. The third and final phase of forebrain development, which lasts until adulthood, is associated with regionalised growth of the various forebrain subdomains and concomitant specification, migration and differentiation of the various neuronal subtypes that make up the adult brain (Eagleson et al., 1998; Wilson and Houart, 2004).

Wnt/β-catenin signalling has been reported to play an essential role during the patterning and differentiation stages of the forebrain. During the patterning stage, low or absent Wnt/β-catenin signalling in the anterior region of the forebrain is required for telencephalic specification, whereas high Wnt/β-catenin signalling, together with BMP, FGF and Shh signalling, is important for diencephalic specification (Wilson and Houart, 2004). Later, during the growth and differentiation stage, Wnt/β-catenin signalling is activated in the anterior region, promoting the differentiation of neural stem/progenitor cells (Kondo et al., 2011; Machon et al., 2007; Marinaro et al., 2012; Peukert et al., 2011). Thus, Wnt/β-catenin signalling is highly dynamic, both temporally and spatially, during forebrain development and understanding how this dynamic nature is exquisitely regulated is essential for understanding how the brain is moulded during development. Although it is clear that the establishment of a low-to-high Wnt gradient across the anterior-posterior axis patterns different domains of the forebrain, only a few regulators have been identified that control Wnt/β-catenin activity in the anterior region at the onset of the third stage (Juraver-Geslin et al., 2011; Peukert et al., 2011). Specifically, the mechanisms that lead to Wnt/β-catenin activation during the later phase of forebrain development are currently unknown.

Fezf2, which is also known as fez/Earmuff, too few, ZNF312 and Zfp312, is a highly conserved gene that encodes a zinc finger transcriptional repressor, which is expressed in the forebrain (Shimizu and Hibi, 2009). Fezf2 homologues have been identified and studied in Drosophila (Weng et al., 2010), zebrafish (Berberoglu et al., 2009; Hashimoto et al., 2000; Levkowitz et al., 2003), mouse (Shimizu and Hibi, 2009; Shimizu et al., 2010) and human (Zhu et al., 2010). All Fezf2 orthologues encode transcription factors characterised by six DNA-binding C2H2-type zinc fingers and an Engrailed homology 1 (Eh1) repressor motif that interacts with Transducin-like enhancer of split (TLE)-type transcriptional co-repressors (Shimizu and Hibi, 2009). Studies in mouse have shown that Fezf2-expressing radial glial cells are multipotent progenitors that generate all major projection neurons and glia of the neocortex (Guo et al., 2013). In addition, Fezf2 controls neuronal subtype differentiation, including that of subplate neurons (Hirata et al., 2004; Rouaux and Arlotta, 2010), specification of subcortical projection neurons in cortex layer V (Chen et al., 2008) and...
patterning of the forebrain and olfactory systems (Shimizu and Hibi, 2009). Furthermore, Fezf2 is required for the establishment of diencephalic subdivisions (Hirata et al., 2006). In *Drosophila*, Fezf2 restricts the developmental potential of intermediate neural progenitors (Weng et al., 2010). In zebrafish, *fezf2* is co-expressed with neural stem markers in the adult brain (Berberoglu et al., 2009), where it controls the development of monoaminergic neurons (Jeong et al., 2006; Levkowitz et al., 2003) and is involved in patterning of the diencephalon (Jeong et al., 2007). More recently, Fezf2 has been reported to possess a unique ability to reprogramme postmitotic neurons in *vivo* (De la Rossa et al., 2013; Rouaux and Arlotta, 2013). Notably, although many roles for Fezf2 have been described, very little is known about the molecular mechanisms underlying its functions during forebrain development.

We have identified *fezf2* as a positive regulator of Wnt/β-catenin signalling in the rostral forebrain, and we have revealed the molecular mechanism by which *fezf2* triggers Wnt signalling and consequent neural progenitor differentiation and forebrain growth in the *Xenopus* embryo. We demonstrate that *fezf2* is expressed in the developing *Xenopus* embryo. Depletion of *fezf2* in embryos results in arrested neural progenitor differentiation, increased apoptosis, and reduction in forebrain size. We also show that *fezf2* promotes Wnt/β-catenin signalling at the differentiation stage, and that this activity is required for proper development of the forebrain. We further reveal that Fezf2 interacts with co-repressors of the Groucho family and, through its repressor activity, restricts the expression of *lhx2* and *lhx9*, which encode two negative regulators of Wnt/β-catenin signalling in the forebrain, thus explaining its Wnt-promoting role. Taken together, we conclude that *fezf2* initiates proper neuronal differentiation in the forebrain by promoting localised Wnt/β-catenin signalling through a double-repressor model.

**RESULTS**

**fezf2 is expressed in the anterior forebrain during early development**

We isolated *fezf2* from an *in vivo* large-scale gain-of-function screen aimed at identifying novel regulators of several signal transduction pathways during early *Xenopus* development (Zhang et al., 2013). Subsequent qPCR analyses revealed that *fezf2* expression begins at the early gastrula stage (stage 10.5), reaching a maximum at the mid-neurula stage (stage 15), at which time its expression decreased slightly and plateaued thereafter (supplementary material Fig. S1). This pattern was very similar to that obtained from whole-exome deep sequencing (Tan et al., 2012). We then assessed the spatial expression pattern of *fezf2* using whole-mount *in situ* hybridization. These data revealed that *fezf2* is expressed in the prospective anterior neural region and presumptive forebrain region from the early neurula stages (stage 15) (supplementary material Fig. S2). At the tailbud stage (stage 28), *fezf2* was expressed in the telencephalon, ventral diencephalon and the eye vesicle (supplementary material Fig. S2). At early tadpole stages (stage 35), the expression of *fezf2* remained restricted to the forebrain and eye vesicle (supplementary material Fig. S2).

**fezf2 is required for proper neuronal differentiation within the forebrain**

To dissect the function of *fezf2*, we first performed a series of knockdown experiments using an antisense morpholino oligonucleotide (MO) targeting the exon 3-intron 3 splice junction of the pre-mRNA (supplementary material Fig. S3A). The knockdown efficiency of this MO was validated using RT-PCR and qPCR (supplementary material Fig. S3A,B).

Embryos injected with control MO exhibited normal forebrain development, whereas *fezf2* MO caused significant disruption in the development of the forebrain, as revealed by diminution in the expression of the rostral forebrain-specific marker *arx* (Fig. 1A) as well as the anterior neural markers *otx2* and *pax6* at stage 30 (supplementary material Fig. S4A) (El-Hodiri et al., 2003). Notably, early forebrain patterning was unaffected in *fezf2* morphants, as stage 15 (early neurula) embryos did not exhibit altered expression of the forebrain markers *arx*, *otx2* and *pax6* (supplementary material Fig. S4B).

To characterise the cell types in the forebrain that were affected by loss of *fezf2*, we injected the *fezf2* MO into one cell of 2-cell stage embryos, and then we assessed the effect of this perturbation on specific cell populations in the injected side of the forebrain versus the control side at stage 30. No significant change was observed in the number of Sox3+ neural progenitor cells in the *fezf2* MO-injected side versus non-injected side (Fig. 1B-D) (Wang et al., 2006). However, *fezf2* knockdowns resulted in a 45% reduction in the number of differentiating neurons, as assayed by immunostaining for the primary neuronal differentiation marker Myelin transcription factor 1 (*MyT1*) (Fig. 1E-G) (Bellefroid et al., 1996). We further confirmed a reduction in differentiated neurons by staining with an acetylated β-tubulin antibody, which labels the axons of differentiated neurons.
(supplementary material Fig. S4La-c). No reduction in either Sox3+ or MyT1+ cells was observed in embryos injected with a control MO (supplementary material Fig. S4C-E,F-H). Therefore, fezf2 is required for neuronal differentiation, but is not essential for the maintenance of neural progenitor cell populations.

One possibility for the reduction in the number of differentiated neurons in the forebrain area is that fezf2 is required for cell survival during differentiation. To address this, we performed TUNEL assays on control versus knockdown sides of the embryos. These experiments revealed that injection of fezf2 MO, but not the control MO, caused a 3-fold increase in the number of apoptotic cells in the knockdown side versus the control side of the forebrain (Fig. 1H-J; supplementary material Fig. S4I-K). Taken together, we conclude that fezf2 controls the transition from neuronal progenitors to differentiated neurons, but is not required for the early forebrain patterning events, nor for the maintenance of neural progenitor cells prior to neuronal differentiation.

**fezf2 promotes Wnt/β-catenin signalling in early embryos**

We next investigated the mechanism(s) by which Fezf2 acts during development. It was first noted during the functional screen (Zhang et al., 2013) that embryos injected with fezf2 mRNA are significantly dorsoanteriorised, resembling LiCl-treated embryos (Kao and Elinson, 1988; Kao et al., 1986) or those with excessive Wnt/β-catenin signalling (Smith and Harland, 1991) (Fig. 2A). Moreover, injection of fezf2 mRNA into early *Xenopus* embryos resulted in an increase in Smad2/3 phosphorylation, which is a measure of TGFβ/Nodal signalling, and a decrease in Smad1/5/8 phosphorylation, which is a measure of BMP signalling (Fig. 2B) (Zhang et al., 2013), changes that are similar to those seen after injection of *wnt8* mRNA in early embryos (supplementary material Fig. S5A). Together, these phenotypic and signalling changes suggested that fezf2 overexpression might lead to hyperactivation of Wnt/β-catenin signalling.

To confirm whether fezf2 is able to activate Wnt/β-catenin signalling, we examined if injection of fezf2 mRNA is able to induce the expression of the immediate Wnt-responsive genes *xnr3* and *siamois (sia)* (Sheldahl et al., 1999). Indeed, overexpressing fezf2 led to a robust increase in the expression level of these two Wnt-responsive genes in early embryos (Fig. 2C,D). In addition, early gastrula stage embryos overexpressing fezf2 exhibited quantitatively higher levels of expression of goosecoid (*gsc*) and chordin (*chd*), two additional Wnt/β-catenin-responsive genes (Pierce and Kimelman, 1995), and led to an expansion of the expression domains of these two genes beyond the dorsal organizer region (supplementary material Fig. SSB-G). By contrast, expression of the ventral markers *vent1* (Sander et al., 2007) and *bmp4* (Baker et al., 1999) was downregulated in fezf2-overexpressing embryos, further confirming
that misexpression of fezf2 leads to a strong dorsoanteriorisation of embryos (supplementary material Fig. SSH-M).

The translocation and nuclear accumulation of β-catenin is a direct indicator of Wnt/β-catenin signalling activation (Cadigan and Nusse, 1997). Hence, we examined nuclear accumulation of β-catenin in control versus fezf2 mRNA-injected embryos, using a DAPI mask to specifically reveal the presence of nuclear β-catenin (Schohl and Fagotto, 2002). In control embryos, nuclear β-catenin was preferentially enriched in the dorsal blastoporal lip of gastrula stage embryos (supplementary material Fig. SSNa,a), consistent with previous findings (Schohl and Fagotto, 2002). However, in fezf2 mRNA-injected embryos, a much stronger nuclear accumulation of β-catenin was found throughout the embryo, suggesting widespread hyperactivation of Wnt/β-catenin signalling (supplementary material Fig. SSNb,b). In addition, injection of fezf2 mRNA into one of the two ventral blastomeres at the 4-cell stage induced axis duplication with complete head in more than 75% of embryos (supplementary material Table S1 experiment I, Fig. SSO,P), as is often observed following ectopic activation of Wnt/β-catenin signalling (Sokol et al., 1991). Furthermore, this fezf2-induced secondary axis induction could be antagonised by co-injecting an N-terminally truncated dominant-negative form of Tcf3 (ΔN51-Tcf3) (supplementary material Table S1 experiments II-1 to II-4) or nkl1 mRNA, a direct inhibitor of Wnt/β-catenin signalling (supplementary material Table S1 experiments II-5 and II-6) (Ishitani et al., 1999; Molenaar et al., 1996). Thus, fezf2 misexpression leads to robust hyperactivation of Wnt/β-catenin signalling.

In order to observe a more direct effect of fezf2 on Wnt/β-catenin signalling, we performed in vivo luciferase assays using a Wnt-responsive construct, TOPFlash (Veeman et al., 2003). Co-injection of fezf2 mRNA with the TOPFlash DNA construct caused an 8-fold increase in luciferase activity over the lacZ (β-gal) control (Fig. 2E), whereas fezf2 mRNA together with the TOPFlash construct, which contains mutated TCF consensus binding motifs, failed to exhibit an increase luciferase activity (supplementary material Fig. SSQ). These experiments confirmed that fezf2 overexpression activates Wnt/β-catenin signalling in early embryos.

A previous investigation has suggested that Fezf2 negatively regulates Wnt/β-catenin signalling in mouse embryonic stem cells (mESCs) by repressing the expression of Wnt ligands (Wang et al., 2011). We tested the expression of several canonical Wnt signalling-related ligands in control versus fezf2-expressing animal cap explants. To induce anterior neuroectoderm, we injected chd mRNA, which encodes a potent BMP antagonist, into early embryos and allowed the explants to develop until stage 15 (Sasai et al., 1995). The expression of wnt1 was slightly increased in fezf2-expressing animal cap explants, whereas the expression of wnt3a and wnt8b remained unchanged (supplementary material Fig. S5R).

Expression of fezf2 colocalises with and is functionally required for active Wnt/β-catenin signalling in the forebrain

We next asked whether fezf2 expression in the forebrain correlates with active Wnt/β-catenin signalling. We isolated ~3 kb of the fezf2 proximal promoter region and used it to drive the expression of Katushka in transgenic embryos (Shcherbo et al., 2007). In addition, we co-integrated a Wnt reporter cassette, 7LEF-dEGFP, with the fezf2-Katushka cassette using our recently developed pTransgenesis system to generate the transgenic embryos (Love et al., 2011; Tran et al., 2010), which allowed us to observe the state of activation of Wnt signalling (Denayer et al., 2006) and fezf2 promoter activity in the same embryos (Fig. 2F). The resulting transgenic embryos exhibited strong colocalisation of dEGFP signal (Wnt) and Katushka signal (fezf2) in the telencephalic and diencephalic areas, although a broader fezf2 expression was observed in the eye, which might reflect the much longer half-life of Katushka relative to dEGFP (Fig. 2G).

In addition, injection of fezf2 MO into 7LEF-dEGFP F1 transgenic embryos led to a significant decrease in dEGFP expression (i.e. in active Wnt signalling) at stage 32 in the forebrain (Fig. 2Ha, arrowhead), compared with control MO-injected embryos (Fig. 2Hb, arrowhead) (Tran et al., 2010). These data indicated that fezf2 expression not only colocalises with active Wnt/β-catenin signalling, but is also functionally required for maintaining active Wnt signalling in the forebrain.

fezf2 overexpression promotes forebrain neuronal differentiation through Wnt/β-catenin signalling

Fezf2 has been reported to induce neuronal differentiation in mESCs, as well as to induce the differentiation of striatal progenitors into telencephalic precursors and corticofugal neurons (Rouaux and Arlotta, 2010; Wang et al., 2011). Based on our findings, we next asked whether fezf2 induces forebrain neuronal differentiation through its ability to activate Wnt signalling. We began by transfecting a construct carrying the mouse Fezf2 gene (pCS107-Fezf2) into an immortalised mouse C17.2 neural stem cell line, together with either empty vector (pCS2) or the Wnt-inhibitory truncated ΔTcf3 construct (pCS107-ΔN51-Tcf3) (Molenaar et al., 1996; Roose et al., 1998), followed by an assessment of neuronal differentiation in these cells (Mi et al., 2005). Transfection of the Fezf2 construct alone induced a significant proportion of the neural stem cells to differentiate into neurons, as assessed by evaluating the formation of neuronal β-tubulin+ axons (Fig. 2ia,c,J). However, this induction was antagonised by co-transfecting the Wnt-inhibitory ΔN51-Tcf3 construct, but not by a control empty vector (Fig. 2ia,d,J). Transfecting the neural stem cells with the ΔN51-Tcf3 construct alone also had no effect (Fig. 2ib,J). These results indicated that fezf2 induces neuronal differentiation in vitro, and that this induction requires Wnt/β-catenin signalling.

To examine whether Fezf2 induces neuronal differentiation through Wnt/β-catenin signalling in vivo, we electroporated a construct containing CMV promoter-driven fezf2 (pCS107 backbone) with or without the Wnt-inhibitory construct (ΔN51-Tcf3) into the third ventricle of stage 26 X. laevis embryos, and allowed them to develop until stage 31 for analysis. Electroporation of pCS107-fezf2 significantly increased the number of differentiated primary neurons (MyT1+) in the forebrain area, as found in previous studies (Fig. 2Ke,L) (Rouaux and Arlotta, 2010; Wang et al., 2011). However, co-electroporation of pCS107-Δzf-2 with pCS107-ΔN51-tcf3 failed to increase the number of MyT1+ cells, suggesting that Fezf2 requires Wnt/β-catenin signalling to induce neuronal differentiation in vivo (Fig. 2Ka,d,M).

Previous studies have shown that neurogenin 1 (ngn1), a gene involved in neuronal differentiation, is inducible by Wnt/β-catenin signalling and is fezf2 responsive (Hirabayashi et al., 2004; Jeong et al., 2006). Therefore, we tested whether the fezf2-induced activation of ngn1 expression is dependent on Wnt/β-catenin signalling. fezf2 mRNA was injected into Xenopus embryos at the 1- to 2-cell stage with or without ΔN51-tcf3 mRNA. Animal cap explants were dissected at stage 8 and collected at stage 20 to assess the expression of ngn1 by qPCR (supplementary material Fig. S5S). Misexpression of fezf2 mRNA induced ngn1 expression; however,
this induction was attenuated when fezf2 mRNA was co-injected with ΔN51-tcf3 mRNA. Injection of either lacZ mRNA (control) or ΔN51-tcf3 mRNA alone had no effect on ngn1 expression in the animal cap explants (Fig. 2M). These results confirmed that Fezf2 promotes neuronal differentiation in vivo in a Wnt-dependent manner.

**fezf2 functions as a transcriptional repressor and governs forebrain neurogenesis through its ability to activate Wnt signalling**

We next asked whether endogenously expressed fezf2 is involved in activating neuronal differentiation through its capacity to activate Wnt signalling. Fezf2 contains two functional domains: a DNA-binding zinc finger domain, and an Eh1 repressor domain that interacts with TLEs (Buscarlet and Stifani, 2007). We therefore constructed an antimorphic form of Fezf2 (VP16-Fezf2) by replacing its Eh1 domain with the transcriptional activator domain of the viral protein VP16, generating a fusion protein that would be expected to function as a transcriptional activator (de Souza et al., 1999; Ferreiro et al., 1998; Latinkic and Smith, 1999; Onichtchouk et al., 1998). We also replaced the Eh1 domain with the transcriptional repressor domain of Drosophila Even-skipped (Eve) (Han and Manley, 1993), and this construct (Eve-Fezf2) would be expected to repress transcription of its target genes, similar to wild-type Fezf2 (Fig. 3A). Injection of mRNA encoding Eve-Fezf2 increased Smad2/3 phosphorylation, similar to that of wild-type Fezf2 (Fig. 3B, lanes 2 and 4), although it failed to inhibit the phosphorylation of Smad1, which might be attributed to the slight differences between the two repressor domains. By contrast, VP16-Fezf2 led to strong ventralisation of embryos (supplementary material Fig. S6A-C), together with a reversed pattern of Smad1/5/8 and Smad2/3 phosphorylation (Fig. 3B, lanes 3 and 4). Hence, we validated the functionality of the antimorphic Fezf2 construct and confirmed that Fezf2 acts as a transcriptional repressor in Xenopus embryos.

**Fig. 3. The Fezf2-regulated endogenous level of Wnt/β-catenin signalling governs forebrain neurogenesis.** (A) Different Fezf2 constructs. Different N-terminal domains (Eh1-repressor, VP16 activator or Eve repressor) are shown in different colours. The zinc-finger DNA-binding domain is shown in blue. (B) Western blot of gastrula stage Xenopus embryos injected with nuclear lacZ (control), eve-fezf2, VP16-fezf2 and wt-fezf2 and assayed for phosphorylated Smad1 or Smad2 and α-Tubulin (loading control). (C) pTransgenesis system transgenic constructs to assess the impact of Fezf2 and/or Wnt activities on forebrain development. (D) Expression of NβT-GFP (a-e, stage 40 embryo) and arx (a’-e’, stage 30 embryo) in the forebrain of transgenic embryos harbouring the transgenes shown in C. Inset (a) shows the fluorescence from Katushka (red). (E) Quantification of neural tissue growth phenotypes from D.
We next investigated whether endogenously augmented Wnt/β-catenin signalling within the fezf2-expressing regions affects forebrain development. We inserted a cassette comprising a neural-specific β-tubulin promoter driving tauGFP (NβT-tauGFP) into the p1 site of the pTransgenesis system to assess differentiated neural tissue in transgenic embryos (Love et al., 2011). The 3.5 kb fezf2 promoter was placed in the p2 site in the opposite orientation to the p1 NβT-tauGFP cassette to minimise potential promoter interference. The p3 cassette was placed directly downstream of the fezf2 promoter so that any gene within the cassette would be expressed under the control of this promoter (Fig. 3C) (Donnelly et al., 2001). In addition to NβT-tauGFP, the forebrain-specific marker arx was also used to monitor the affected neural tissue in different transgenic embryos. The control transgenic construct with Katushka placed in the p3 position resulted in normal forebrain development. We inserted a cassette comprising a neural-specific β-tubulin promoter driving tauGFP (NβT-tauGFP) into the p1 site of the pTransgenesis system to assess differentiated neural tissue in transgenic embryos (Love et al., 2011). The 3.5 kb p1 site of the pTransgenesis system to assess differentiated neural tissue in transgenic embryos (Love et al., 2011). The 3.5 kb p1 site of the pTransgenesis system to assess differentiated neural tissue in transgenic embryos (Love et al., 2011).

Thus, our data provide compelling evidence that Fezf2 interacts with members of Groucho family, (A) Tle1, Tle2, Tle4 and Aes constructs. Note that Aes lacks the protein-interaction WD domain. (B) Wild-type Fezf2 and ΔEh1-Fezf2 with a mutated Eh1 domain. (C) Immunoprecipitation of extracts from Xenopus embryos injected with different combinations of the indicated mRNAs, showing that Fezf2 interacts with Tle1, Tle2 and Tle4. (lanes 6, 8 and 12) but not Aes (lanes 14, 15). The Eh1 domain is required for the proper interaction between Fezf2 and Tle1/2/4 (lanes 6, 7, 8 and 9, 12 and 13).

Fezf2 physically interacts with Groucho family co-repressors via its N-terminal Eh1 domain

To investigate the mechanism by which Fezf2 promotes Wnt/β-catenin signalling while acting as a transcriptional repressor, we first examined whether Fezf2 can physically interact with TLEs via its Eh1 domain (Buscarlet et al., 2008; Gasperowicz and Otto, 2005). Amongst the four TLEs found in Xenopus, three (Tle1, Tle2 and Tle4) possess the Eh1-interacting WD domain (Fig. 4A) (Rodh et al., 2010). In an in vivo co-immunoprecipitation assay performed with gastrula stage (10.5) embryos, Fezf2 interacted with all three TLEs that possess the Eh1-interacting WD domain (Fig. 4C, lanes 6, 8 and 12). Aes, the only TLE that does not possess a WD domain, did not interact with Fezf2 (Fig. 4C, lane 14). In addition, a mutated Fezf2 with five conserved hydrophobic amino acid residues removed within the Eh1 domain (ΔEh1-Fezf2, Fig. 4B) lost its ability to interact with the TLEs (Fig. 4C, lanes 7, 9 and 13), confirming Eh1 itself as the interaction domain between Fezf2 and TLEs.

Finally, since Tle4 can complex with Tcf and thus is an important component of Wnt signalling, we examined whether Fezf2 affects Wnt signalling by titrating Tle4 away from the Tle4-Tcf complex. We generated an additional fezf2 mutant (C284S) that has a point mutation in the DNA-binding zinc finger domain but an intact Eh1 domain (Levkowitz et al., 2003). In contrast to wild-type fezf2, ventral blastomere injection of fezf2 C284S mRNA was unable to induce anterior structures or secondary axes (supplementary material Table S1 experiment IV-3) (Levkowitz et al., 2003). Thus, our data provide compelling evidence that Fezf2 interacts with Groucho family co-repressors through its Eh1 domain and acts as a transcriptional repressor.

**Fezf2 represses lhx2 and lhx9 expression to promote Wnt/β-catenin signalling in the forebrain area**

To investigate the regulatory mechanism by which fezf2 activates Wnt/β-catenin signalling within the forebrain, we noted previous reports suggesting that Fezf2 binds to the promoter region of lhx2 (Chen et al., 2011; Lodato et al., 2014). Furthermore, we noted that lhx2 and lhx9 inhibit Wnt/β-catenin signalling in the forebrain (Chen et al., 2011; Peukert et al., 2011). We therefore examined whether Fezf2 promotes Wnt signalling by repressing the expression of lhx2 and lhx9, thus acting in a double-repression model. We first performed ChIP-qPCR experiments in stage 15 embryos to confirm whether Fezf2 directly binds to the promoter region of lhx2 in Xenopus. Since no Fezf2 antibodies were available in Xenopus, we utilised a FLAG-tagged version of Fezf2 in Xenopus embryos for co-immunoprecipitation with anti-FLAG antibody, a strategy successfully validated by using a FLAG-tagged FoxH1 protein on the brachyury promoter (supplementary material Fig. S7A) (Akkers et al., 2012, 2010). We then identified three conserved regions within ~15 kb upstream of the lhx2 transcription start site by sequence homology analysis, and then used these regions for ChIP-qPCR analysis (supplementary material Fig. S7B).

A high ChIP enrichment was detected around the ~12 kb region (Fig. 5A, region 1; supplementary material Fig. S7B), whereas no ChIP enrichments were found in the other two regions tested (Fig. 5A, regions 2 and 3; supplementary material Fig. S7B).

We were unable to perform ChIP-qPCR within the promoter region of lhx9 as the available sequence data for this region in the Xenopus tropicalis genome is incomplete. Instead, we employed an alternate strategy to determine whether Fezf2 directly influences the transcriptional activity of lhx9. Antimorphic VP16-Fezf2, if activated, should be able to trigger the expression of Fezf2 direct target genes, even in the absence of protein synthesis. Hence, we made a VP16-Fezf2 construct fused to the 3’-end of human glucocorticoid receptor (hGR) (termed p3hGR-VP16-Fezf2), which can be activated...
by the addition of dexamethasone (DEX) (Ryan et al., 2004). Reassuringly, we found that animal caps overexpressing p3hGR-VP16-Fezf2 were able to activate the expression of lhx2 and lhx9 in the presence of DEX, but not in its absence (supplementary material Fig. S8A,B). Furthermore, we were able to show that the potent protein synthesis inhibitor cycloheximide (CHX) (Saka et al., 2000) had no effect on the expression level of lhx2 or lhx9 in animals caps overexpressing p3hGR-VP16-Fezf2 when added alone (supplementary material Fig. S8A,B). Importantly, however, treatment of animals caps overexpressing p3hGR-VP16-Fezf2 with both CHX and DEX led to 2-fold and 6-fold increases in the expression levels of lhx2 and lhx9, respectively (Fig. 5B,C). Thus, p3hGR-VP16-Fezf2 is able to activate the expression of lhx2 and lhx9 even in the absence of de novo protein synthesis, providing compelling evidence that both of these genes are direct targets of Fezf2.

We next assessed whether lhx2 and/or lhx9 act downstream of fezf2 during forebrain development. Both lhx2 and lhx9 are expressed in the anterior neural ectoderm (supplementary material Fig. S2). Animal cap explants neuralised by chd and aged to stage 20 expressed significant levels of both lhx2 and lhx9 compared with control lacZ-injected embryos, indicating that these explants recapitulate anterior neuroectoderm (supplementary material Fig. S8C,D). However, the expression of both lhx2 and lhx9 was inhibited by co-expressing fezf2 in chd-neuralised animal cap explants (Fig. 5D,E), suggesting that Fezf2 is a potent negative regulator of both genes. By contrast, fezf2 knockdown following injection of 5 ng fezf2 MO per embryo resulted in an expansion of both the lhx2 and lhx9 expression domains in the forebrain area of stage 28 embryos, including an expansion of lhx2 expression in the epithalamus (Fig. 5F,G; supplementary material Fig. S8E).

We next designed and validated MOs targeting lhx2 and lhx9 (supplementary material Fig. S8F-I) and examined whether the activity of fezf2 could be rescued by simultaneously knocking down both lhx2 and lhx9. We found that, whereas most embryos injected with fezf2 MO displayed reduced expression of arx, embryos injected...
with fezf2 and lhx2/lhx9 MOs showed partial rescue in the expression of arx at stage 28 (Fig. 5H; supplementary material Fig. S8J). Furthermore, no significant changes in arx expression were observed in embryos injected with lhx2/lhx9 MOs alone (Fig. 5H; supplementary material Fig. S8J) (Peukert et al., 2011). Hence, we conclude that lhx2 and lhx9 function downstream of Fezf2 in vivo.

We next tested whether lhx2 and lhx9 act as an intermediary in the ability of Fezf2 to activate ngn1 expression in the forebrain. Whereas fezf2 morphant embryos were almost devoid of ngn1 expression in the forebrain (Fig. 5I, arrowheads), ngn1 expression was partially restored when lhx2/lhx9 MOs were co-injected with fezf2 MO (Fig. 5I; supplementary material Fig. S8K). We also found that, although fezf2 overexpression in chd-neuralised explants induced the expression of the Wnt-responsive gene xnr3 (Fig. 5J), this induction was attenuated by co-injection of lhx2 and lhx9 mRNAs (Fig. 5J). Moreover, the high level of ngn1 induced by fezf2 overexpression was also significantly attenuated by combined overexpression of lhx2 and lhx9 (Fig. 5K), suggesting that lhx2 and lhx9 are potent inhibitors of Wnt signalling in Xenopus neuroectoderm. Taken together, these findings suggest that fezf2 inhibits the expression of the Wnt-responsive transcription factors lhx2 and lhx9, thus promoting ngn1 expression and, subsequently, neurogenesis in the forebrain.

DISCUSSION

Growth and differentiation are crucial steps during the development and maturation of the forebrain. Here we propose that Fezf2 plays a crucial role during the regulation of forebrain neurogenesis through its ability to modulate Wnt/β-catenin signalling by a double-repressor model (Fig. 6A). Fezf2 in the forebrain area represses the expression of the Wnt-inhibitory genes lhx2 and lhx9, thus permitting Wnt/β-catenin signalling to be activated. Consequent activation of Wnt/β-catenin signalling allows the Tcf complex to interact with β-catenin, freeing it from an inhibitory state (Lepourcelet and Shvidrasani, 2002). As a result, ngn1 expression is switched on (Hirabayashi et al., 2004; Israsena et al., 2004), thus allowing and promoting the differentiation of neural stem cells/progenitors into mature neurons (Hirabayashi et al., 2004; Jeong et al., 2006; Munji et al., 2011). By contrast, in the absence of Fezf2, Lhx2 and Lhx9 repress Wnt/β-catenin signalling (Peukert et al., 2011), which leads to impaired ngn1 expression and increased apoptosis in committed neural stem cells/progenitors (Fig. 6B).

Stage-dependent regulation of Wnt/β-catenin signalling plays an essential role during anterior neural development. During the patterning stage, a low-to-high Wnt gradient across the anterior-posterior axis of the forebrain is required to establish telencephalon-diencephalon-midbrain identity (Heisenberg et al., 2001). By contrast, after the patterning stage is complete and neuronal differentiation begins, a number of Wnt ligands, including Wnt2b, Wnt5a/b, Wnt7b and Wnt8b, are expressed in ventral diencephalic and telencephalic areas (Quinlan et al., 2009). Expression of such Wnts activates Wnt/β-catenin signalling within the forebrain thereby promoting several events in neuronal differentiation, including the formation of cortical neurons, neuronal stem cells, basal progenitors and DA neurons (Castelo-Branco et al., 2003; Hirabayashi et al., 2004; Israsena et al., 2004; Kuwahara et al., 2010; Munji et al., 2011). In addition, an increase in Wnt activity in the mouse cerebrum has been reported to result in excessive neurogenesis, which further emphasises the promotional role of Wnt signalling in neurogenic activities (Seib et al., 2013). Our finding that Fezf2 may, at least in part, promote neurogenesis by its ability to activate Wnt signalling provides an additional layer to the exquisite temporal and spatial regulation of Wnt signalling that occurs during the differentiation phase of forebrain development.

Both positive and negative regulators are employed in modulating the transcriptional output of Wnt/β-catenin signalling in the forebrain, and a balance between agonising and antagonising regulatory mechanisms is employed to achieve this. Previous findings have identified several negative regulators of Wnt signalling, such as barhl2 and lhx2/lhx9, in the forebrain (Hou et al., 2013; Juraver-Geslin et al., 2011; Peukert et al., 2011). However, no positive regulators have been identified to counterbalance the Wnt-inhibitory mechanisms in this area to ensure the proper temporal and spatial control of Wnt signalling and the consequent differentiation of progenitors after the initial
suggesting the pivotal role of subdivisions (Levkowitz et al., 2003), and defects in reciprocal defects, including loss of monoaminergic neurons (Jeong et al., 2010; Wang et al., 2011). Loss of neuronal growth and differentiation, et al., 2011). Whereas all previously identified genes act to inhibit barhl2 expression. By contrast, our study investigated more directly the effect of fezf2 upregulation and downregulation on Wnt/β-catenin activity using a number of assays, which all consistently showed that fezf2 increased the activity of Wnt/β-catenin signalling. Furthermore, it is also notable that, when we assessed the effect of fezf2 on the expression of genes encoding Wnt ligands, we found no effect in the cases of wnt3a and wnt8b, and an increase in the case of wnt1. Indeed, our results are consistent with established models that place Wnt/β-catenin signalling as an essential and stimulating factor that promotes the differentiation of neural stem cells/progenitors (Juraver-Geslin et al., 2011; Potok et al., 2008).

Functionally, several families of genes have been reported to be important for neuronal growth and differentiation in the forebrain, including the iroquois gene family (Gómez-Skarmeta and Modolell, 2002), fezf1/2 (Hirata et al., 2006; Shimizu et al., 2010), barhh2 (Juraver-Geslin et al., 2011) and lhx2/lhx9 (Peukert et al., 2011). Whereas all previously identified genes act to inhibit neuronal growth and differentiation, fezf2 plays a promotional role in these processes (Rouaux and Arlotta, 2010, 2013; Shimizu et al., 2010; Wang et al., 2011). Loss of fezf2 results in various forebrain defects, including loss of monoaminergic neurons (Jeong et al., 2010; Levkovitz et al., 2003), disruption of diencephalon subdivisions (Levkowitz et al., 2003), and defects in reciprocal projections between thalamus and cerebral cortex (Komuta et al., 2007). It is noteworthy that all the above developmental defects can be attributed to insufficient or deficient neuronal differentiation, suggesting the pivotal role of fezf2 in this process.

It is interesting that, although the expression of fezf2 in the forebrain starts from the early patterning stage, its effect on Wnt/β-catenin signalling only becomes apparent from the tailbud stage at the onset of neuronal differentiation. One possibility that might account for this delayed function is that the Wnt-agonising activity of Fezf2 requires the participation of one or more unknown co-factors that are absent during the earlier neural patterning stage of development. It is also possible that, at the early stages, the anterior neuroectoderm is protected from Wnt signalling by several layers of Wnt-antagonising mechanisms.

A second interesting question is whether there are other transcription targets, in addition to lhx2 and lhx9, that mediate some of the effects of Fezf2 during forebrain development. Since overexpression of fezf2 can lead to Wnt activation in early stage embryos, when neither lhx2 nor lhx9 is yet expressed, it stands to reason that Fezf2 must be able to regulate the expression of additional targets that are responsible for the expanded activation of Wnt signalling in the early dorsoanteriorisation of embryos. Indeed, a recent study has revealed additional potential target genes of Fezf2 in cultured cortical progenitors (Lodato et al., 2014). Thus, an important future line of work will be to determine the function of these additional targets, including whether they also impinge on Wnt signalling.

Fezf2 has recently attracted great interest in the field of neural stem cell biology, as its expression marks multipotent progenitor cells and manipulating fezf2 expression is able to provide a unique method for reprogramming postmitotic neurons within the mammalian neocortex (De la Rossa et al., 2013; Guo et al., 2013; Rouaux and Arlotta, 2010, 2013). In a series of unrelated studies, Wnt signalling, as the central signalling cascade regulated by fezf2, has been suggested to regulate neuronal differentiation and the assembly of neural connectivity and synapse formation and function (Munjí et al., 2011; Oliva et al., 2013). Our studies, which link Fezf2 activity with Wnt signalling, suggest the tantalising possibility that the molecular mechanisms by which Fezf2 mediates lineage fate determination, reprogramming and plasticity might be mediated through its capacity to activate Wnt/β-catenin signalling. Our studies further suggest that modulating the activity of Wnt/β-catenin signalling, through the expression of Fezf2, might provide a powerful means of modulating the differentiation fates of neural stem cells, reprogramming postmitotic neurons or inducing neuronal plasticity.

MATERIALS AND METHODS

Sequences and constructs
Details of X. tropicalis fezf2, lhx2 and lhx9 constructs, constructs for antimorphic studies and restriction enzyme-mediated integration (REMI) experiments using the pTransgenesis recombinase system and associated cloning primers are provided in supplementary Materials and Methods and Table S2.

mRNA microinjections
Microinjection of mRNA was performed as described previously, with lacZ mRNA co-injected as a tracer in some cases (Bourguignon et al., 1998). For further details see supplementary Materials and Methods.

MO design and injection
MOs designed against X. tropicalis genes were supplied by Gene Tools. Typically, 10 ng MO was injected per X. tropicalis embryo at the 1- to 2-cell stage. Further details, including MO sequences, are provided in the supplementary Materials and Methods.

Electroporation
Electroporation was performed as described (Falk et al., 2007). Briefly, 50 nl of 2 µg/µl plasmid mixtures were injected into the subventricular vesicles of stage 26 Xenopus embryos followed by electric pulses. Electroporated embryos were harvested at stage 30 for analysis.

In situ hybridisation
Antisense digoxigenin-labelled RNA probes for whole-mount in situ hybridisation were prepared by T7 RNA polymerase-mediated transcription (Roche). X-Gal staining and in situ hybridisation were carried out as previously described (Bourguignon et al., 1998).

Immunofluorescence, TUNEL staining and image processing
Fixed Xenopus embryos were cryosectioned for immunofluorescence (see supplementary Materials and Methods). Mouse c17.2 cells were grown in Lab-TEK II chambered slides (NUNC) and fixed with MEMFA. Details of c17.2 cell culture and transfection are provided in the supplementary Materials and Methods. Primary antibodies were: anti-Sox3 (a kind gift from the Klymokovsky lab; 1:1000) (Bonev et al. 2012), anti-MyT1 (1:1000) (Sahberwal et al., 2009) and mouse anti-acetylated tubulin (Sigma, T7451; 1:1000). Secondary antibodies were: anti-rabbit/mouse Alexa 488/568/647 (Invitrogen; 1:500). TMR Red (Roche) was used in TUNEL assays. Nuclei were stained with DAPI. Images were taken with a Nikon Eclipse 80i or an Olympus 2X81 confocal microscope and processed with ImageJ (NIH) software.

In vivo luciferase assay
Briefly, 50 pg pTK-Renilla and 100 pg M50 TOPFlash (Addgene, 12456) or M51 FOPFlash (Addgene, 12457) (Veenman et al., 2003) were co-injected with 200 pg of either fezf2 or control lacZ mRNA. Injected Xenopus
embryos were collected at stage 10.5 and analysed with the DLR system (Promega). For further details see supplementary Materials and Methods.

**DEX induction of human glucocorticoid receptor fusion protein**
The DEX-inducible VP16-Fezf2 construct was made by fusing the VP16-Fezf2 protein to the 3′-end of human glucocorticoid receptor (hGR) using XbaI-Nol restriction sites (Ryan et al., 2004). 500 pg of mRNA was injected into X. laevis embryos at the 1- to 2-cell stage. Animal cap explants (see supplementary Materials and Methods) were excised at stage 8 and allowed to develop until stage 12. A final concentration of 5 µg/ml CHX with or without 2 mM DEX in ethanol was used. Carrier alone (0.05% ethanol) was used as control. Animal cap explants were collected 2 h post treatment (Saka et al., 2000).

**Smad phosphorylation analysis**
The phosphorylation status of signalling molecules in gastrula stage X. laevis embryos was determined by western blot analysis as described in the supplementary Materials and Methods.

**ChIP-qPCR**
Chromatin co-immunoprecipitation (ChIP) was performed using a modification of published methods (Akkers et al., 2012; Blythe et al., 2009). Briefly, X. tropicalis embryos were injected with 50 pg FLAG-tagged fezf2 mRNA, harvested at stage 15, crosslinked with 3.7% formaldehyde for 15 min and stored at –80°C until use. Approximately 300 embryos were used for each sample. Fezf2-binding fragments were enriched using anti-FLAG M2 antibody (Sigma) as described (Akkers et al., 2012). DNA regional enrichment was analysed by quantitative PCR (qPCR). qPCR primers are detailed in supplementary material Table S2. For further details see the supplementary Materials and Methods.

**Statistical analysis**
For Sox3, MyT1 and TUNEL assays, positive cells were counted on two consecutive sections in the corresponding brain area for determination of the mean (Bonev et al., 2012); is the number of individual embryos from at least three independent fertilisations and injections. For qPCR analyses, collected animal cap explants from individual experiments were pooled for RNA extraction, and all data were from at least three independent experiments (n=3), unless otherwise indicated. Statistical analysis was performed using GraphPad Prism software with either two-tailed unpaired Student’s t-test (for two samples) or two-tailed unpaired one-way ANOVA (for multiple samples) and s.e.m. was calculated.

**Acknowledgements**
We thank Christof Niehrs, Christine Holt, Shoko Ishibashi, Boyan Bonev, Nancy Papalopulu, Corinne Houart and Gert Jan Veenstra for providing reagents, instruments and/or advice.

**Competing interests**
The authors declare no competing financial interests.

**Author contributions**
S.Z. designed, performed and analysed most of the experiments and co-wrote the manuscript. P.L. performed the fezf2, Ixh2 and Ixh9 in situ in supplementary material Figs S2 and S8. K.V. provided the F1.5-2 Wnt reporter line and facilitated the production of the Wnt-responsive transgenic embryos. E.A. supervised the project and co-wrote the manuscript.

**Funding**
This work was supported by two Healing Foundation Studentships to S.Z. and J.L.; two project grants from the Healing Foundation to S.Z./E.A. and J.L./E.A., respectively, a Programme Grant from the Wellcome Trust to E.A. [WT082450MA]; and an Institutional Strategic Support Grant from the Wellcome Trust [097820/21/112]. Deposited in PMC for immediate release.

**Supplementary material**
Supplementary material available online at http://dev.biologists.org/lookup/suppl/doi:10.1242/dev.115691/-/DC1

**References**


Sequences and constructs

The original *X. tropicalis* fezf2 EST clone identified in the functional screen was TGas068O03. The coding sequence for *Xenopus tropicalis* fezf2 was amplified by PCR and subcloned into the ClaI-SalI site of a modified pCS107 vector. *X. tropicalis* tle4-HA and aes-HA constructs were generously provided by Nancy Papalopulu (Roth et al., 2010). The list of primers used for cloning and qPCR analyses are provided in Supplementary Table S2. The qPCR primers used for identifying the temporal expression patterns of fezf2 (fezf2 and rpl8) were purchased from Applied Biosystems as TaqMan probes. HA and FLAG tags were added to the C-terminal end of Fezf2.

For the antimorphic studies, the VP16 transactivation domain was amplified from VP16-XBlimp (a kind gift by Christof Niehrs) and fused to the C-terminal zinc-finger domain of fezf2 using HindIII to form VP16-Fezf2. Similarly, the Eve-repressor domain cloned from *Drosophila* cDNA was fused to the C-terminal zinc-finger domain of fezf2 using HindIII to form Eve-Fezf2. Part of the En1 sequence (amino acid 30-34, FSIER) was removed with PCR and reconstructed to generate ΔEn1-Fezf2-pCS107.

The M50 TOPFlash (Addgene 12456) and M51 FOPFlash (Addgene 12457, contains mutated TCF/LEF binding sites and served as negative control) were originated from the Moon laboratory and purchased from Addgene. The pTK-Renilla plasmid (Promega) used as internal control.

Microinjections and embryo processing

Microinjection of mRNA was performed as described previously with lacZ mRNA co-injected as a tracer in some cases (Bourguignon et al., 1998). For microinjections, all pCS107-derived plasmids were linearised with Asc I (NEB); pCS2-derived
plasmids were linearised with Not I (NEB). pSPORT6-Msx1 was linearised with Not I. Ambion® mMessenger SP6 kit and MegaClear Spin columns were used for in vitro transcription of all mRNA transcripts.

Animal cap explants were isolated from mid-blastula (stage 8-8.5) embryos and cultured in ¾ NAM until specified stages. Collected embryos or explants were stored in Ambion® RNAlater solution and extracted using Qiagen RNEasy mini kit. For injection embryos or explants subjected to qPCR analysis, three replicates were used to generate statistical results. qPCR analysis was performed using ABI high-capacity RNA-to-cDNA reverse transcription kit, ABI SYBR Fast or ABI TaqMan Fast reagent depending on experiment requirements. Data collection was performed on an ABI StepOnePlus machine.

RNA injection amounts for embryos and animal cap explants were as follows: fezf2: 100 pg; lhx2: 400 pg; lhx9: 400 pg; ∆NTcf3: 200 pg.

Morpholino (MO) design and injection

All MO experiments were performed in X. tropicalis with MOs specifically designed against the X. tropicalis genes and supplied by Gene Tools Inc. Some MOs were FITC-labelled to provide information on injection quality and to provide a measure of lineage labelling. The control MO was the standard Gene Tools control 25-mer (5’-CCTCTTACCTCACAAATTATA-3’). The fezf2 e3i3 splicing MO sequence was 5’-AGGATTTCCCCGTACCGTACCTGT-3’. The lhx2 i2e3 splicing MO sequence was ATCGCCTGTGCAATCAGAACCAGGA. The lhx9 e1i1 splicing MO sequence was GGAGAGACGCGTACCTTACTCTTACTTTT. For the primer sequences used in validating the MO function, refer to Supplementary Table 2. 10 ng of MO (5
Development 141: doi:10.1242/dev.115691: Supplementary Material

ng x 2) was injected into each *X. tropicalis* embryo at the 1-2 cell stage unless specified.

**Restriction enzyme mediated integration (REMI) and fluorescence stereoscope imaging**

Construct assembly for REMI experiments was done using the pTransgenesis recombination system (Love et al., 2011). Briefly, either an NβT-tauGFP or an 7LEF-dEGFP (Denayer et al., 2006) cassette was placed in the p1 position such that both promoters transcribed in opposite directions. The 3kb *fezf2* core promoter was isolated and placed in p3 site. Several p3 constructs were made from a starting vector containing a 2A construct flanked by two pairs of restriction enzyme sites. The VP16-Fezf2 construct has been described. The stabilised β-catenin construct was made by removing the ~270 bp region encoding the N-terminal GSK3β binding domain (Aberle et al., 1997). The dominant-negative Tcf3 construct was made by removing the ~150 bp N-terminal β-catenin binding domain (Molenaar et al., 1996). The constitutively-active GSK3β was made by mutating the serine 9 into alanine thus preventing its inhibition by PI3K/AKT signalling (Stambolic and Woodgett, 1994; Sutherland et al., 1993). Only VP16-Fezf2 was inserted upstream of the 2A short peptide sequence, while the other inserts were all placed downstream of the 2A sequence. The p1, p2, and p3 constructs were integrated into the pDEST R4-R3 destination vector and subsequently linearised using Aat II (NEB) for integration. Standard REMI was performed as described (Ishibashi et al., 2008). After REMI, embryos were incubated in 16°C for 4 days (for *in situ* hybridisation) or 7 days (for immunofluorescence microscopy). Images were taken using a Leica M165FC stereoscope with colour CCD module attached.
Western blot and in vivo co-immunoprecipitation

For Western Blot analyses on the phosphorylation status of signalling molecules, each 7 injected *X. laevis* embryos were collected as a group at gastrula stage (10.5), extracted, and homogenized with SDS loading buffer for Western blot analysis. The Western blot protocol for analysing endogenous 1/5/8 and Smad2/3 has been described (Dorey and Hill, 2006). For RNA injection amounts, wild-type *fezf2*: 1ng; Eve-*fezf2*: 200pg; VP16-*fezf2*: 200pg.

For *in vivo* co-immunoprecipitation, 50 *X. laevis* embryos were injected with tagged mRNA at 1-2 cell stage as amounts followed: *fezf2*-HA, 500 pg; ∆Eh1-*fezf2*-HA, 500 pg; *tle1*-FLAG, 500 pg; *tle2*-FLAG, 500 pg; *tle4*-FLAG, 500 pg; *tes*-FLAG, 500pg; *wt-Fezf2*-FLAG, 500 pg; Each injection was supplemented with GFP mRNA to achieve a total of 2 ng mRNA. Embryos were collected and homogenised at stage 10.5 using a modified IP-lysis buffer (50mM Tris-acetate pH 7.5, 300 mM NaCl, 1 mg/ml BSA, 2% NP40, protease inhibitor, and phosphatase inhibitor) followed by Freon extraction to remove excessive lipid in the extract. 10 µl of supernatant was kept as total input. 2 µg of anti-HA (Invitrogen) or anti-FLAG M2 (Sigma-Aldrich) antibody was added into 500µl extract and rotated for 2 hours at 4°C. Following the addition of 30 µl pre-incubated Protein A/G Sepharose (Santa Cruz), samples were rotated overnight at 4°C. Four rounds of washings were performed with washing buffer (50mM Tris-acetate pH 7.5, 300 mM NaCl, 1 mg/ml BSA, 0.5% NP40, protease inhibitor, and phosphatase inhibitor) and Sepharose beads were boiled with 20 µl of SDS-loading buffer for 10 minutes. The bead/buffer mix was loaded on a 10% SDS-PAGE gel.
Western blot was performed on a semi-dry system according to the manufacturer’s instructions (Hoefer). PVDF membrane (Millipore) was blocked with 5% dry milk powder in TBS containing 0.1% Tween 20 for 1 hour followed by incubation with anti-Flag-HRP (1:10000, Sigma) or anti-HA-HRP (1:50000, Roche) antibodies in blocking buffer overnight. Following three washing steps in TBS containing 0.1% Tween 20. Blots were developed using Immobilon ECL reagents (Millipore).

**Cell culture transfections**

Mouse c17.2 neuronal progenitor cells (ATCC) were a kind gift from Nancy Papalopulu. Briefly, cells were maintained in DMEM supplemented with 10% FBS with penicillin/streptomycin. Mouse *Fezf2* and *ΔNTcf3* plasmids were cloned using primers described into pCS107 vector. Plasmid DNA constructs were transfected into cells plated in LAB-TEK II chambered slides (NUNC) and allowed to proliferate until 10-15% confluence before transfection using Lipofectamin 2000 following manufacturer’s instruction (Invitrogen). After transfection, the cells were incubated in DMEM with 10% FBS for 1 day and medium was subsequently changed to DMEM with 1% FBS to allow differentiation for 4 days. The following amounts of plasmid were used: mouse *fezf2*, 1 µg; mouse *ΔNTcf3*, 1 µg. Each transfection was supplemented with empty pCS107 vector to a total of 2 µg DNA.

**Cryosectioning**

For *X. tropicalis* immunohistochemistry, embryos were fixed overnight at 4°C using MEMFA (3.7% formaldehyde, 1x MEM salts) and dehydrated in methanol. After rehydration using PBS, embryos were transferred into 15% fish gelatine/15% sucrose for 16 hours, sectioned on a cryostat (Leica CM3050) using 12 micron slice thickness and stained following standard protocols (Regad et al., 2007).
References


Figure S1. Temporal expression pattern of *X. tropicalis* *fezf2* revealed by qPCR analysis at different stages, including fertilised egg (FE), blastula (stage 8), gastrula (stage 10.5), neurula (stage 15-20), and tailbud (stage 22-24) (*n*=3 replicates). Error bars represent ±s. e. m.
Figure S2. Comparison of expression pattern of *fezf2* expression relative to various neural markers at different stages, related to Figure 1. Anterior is to the bottom in stage 15 and 20 embryos (frontal view), and to the left in stage 28 and 35 embryos (lateral view).
Figure S3. (A) Schematic of fezf2 MO design and knockdown efficiency. The MO targets the exon3-intron3 junction (above) and semi-quantitative PCR analysis shows mature fezf2 mRNA levels in stage 24 embryos (below), injected with control MO (1) or fezf2 MO (2). Black arrow pair indicates the position of validation primers for RT-PCR analysis, the forward primer overlaps the exon3-exon4 junction. (B) qPCR results, n=3 replicates. In both cases, the ribosomal protein L8 (rpl8) gene was used as an internal control.
Figure S4 (related to Figure 1). *fezf2* knockdown, but not control MO knockdown, leads to defects in forebrain neuronal differentiation. (A) *fezf2* knockdown led to defects in forebrain development after initial patterning stage. Whole-mount *in situ*
hybridisation analyses on control versus *fezf2* MO injected stage 28 embryos, stained using the forebrain-specific markers, *otx2* and *pax6*. (B) *fezf2* knockdown did not cause defects in early forebrain patterning, as revealed by whole-mount in situ hybridisation on control versus *fezf2* MO injected stage 17 embryos, stained using the forebrain-specific markers *arx*, *otx2*, and *pax6*. Anterior is to the bottom. (C-H) 1 of 2 blastomeres at 2-cell stage was injected with control MO, cultured to stage 30, fixed sectioned transversely across the forebrain and stained via immunofluorescence for the transcription factor Sox3 (marker for neural progenitors) (C-D) or MyT1 (marker for differentiated primary neurons) (F-G). (C) Merged image. (D) Sox3 staining alone. (E). Statistical analysis of Sox3+ cells in control MO injected side relative to the uninjected side of the forebrain (*n*=3 embryos, no significant difference). The uninjected side has been normalised to 100%. (F) Merged image. (G) MyT1 staining alone. (H) Statistical analysis of MyT1+ cells in control MO injected side relative to the uninjected side of the forebrain (*n*=3 embryos, no significant difference). The uninjected side has been normalised to 100%. (I-K) Transverse sections were prepared as for panels C-D and then processed for TUNEL staining. (I) Merged image. (J) TUNEL-positive cells alone. (K) Percentage of the TUNEL-positive cells in the control MO injected side compared to the uninjected side (*n*=3 embryos). In all cases, the FITC tag on the control MO was used to identify the injected side; DAPI was used to stain nuclei. Error bars represent ± s.e.m. Scale bar: 25 μM. ns: not significant. (L) (a-b) Immunofluorescence staining using the neuronal differentiation marker, N-tubulin, on stage 32 embryos injected with 10 ng of control or *fezf2* MO. (a) control MO; (b) *fezf2* MO, showing a strong reduction of N-tubulin staining in the rostral area. (c) Sections of stage 32 embryos at the prethalamus level and stained with N-tubulin antibody. Embryos were injected with 5 ng of *fezf2* MO into one of the two
blastomeres at the 2-cell stage. A strong reduction of N-tubulin staining was observed in the injected side. Arrowhead: injected side. DAPI was used to provide global visualisation on the head structure. In all cases, error bars represent ±s. e. m.
Figure S5 (related to Figure 2). *fezf2* promotes Wnt/β-catenin signalling. (A) *wnt8* mis-expression inhibited BMP signalling while activating TGF-β/Nodal signalling. 50 pg of either nuclear β-gal mRNA or *wnt8a* mRNA was injected into *X. laevis* embryos.
at 1-2 cell stage and collected at the gastrula stage (10.5) for Western blot analysis. Phospho-Smad 2/3 antibody (TGF-β/Nodal signalling) or phospho-Smad 1/5/8 (BMP signalling) were used assay for the activation states of TGF-β/Nodal or BMP signalling. A significant increase on the phosphorylation level of Smad 2/3 was observed together with significant decrease on the phosphorylation level of Smad 1/5/8 was seen in wnt8 mRNA injected embryos. (B-G) fezf2 mis-expression promotes Wnt-responsive dorsal markers goosecoid and chordin expression. In all cases ribosomal protein L8 (rpl8) gene was used as internal control for qPCR analysis. (B-D) goosecoid expression. (B) Uninjected control embryo. (C) fezf2 mRNA overexpressing embryo. (D) qPCR analysis, showing an increase of goosecoid expression (n=3 replicates, P<0.05). (E-G) chordin expression. (E) Uninjected control embryo. (F) fezf2 mRNA overexpressing embryo. (G) qPCR analysis, showing an increase of chordin expression (n=3 replicates, P<0.001). (H-M) fezf2 mis-expression inhibits ventral markers vent1 and bmp4 expression. Embryo treatments are same as in (B-G). (H-J) vent1 expression. (H) Uninjected control embryo. (I) fezf2 mRNA overexpressing embryo. (J) qPCR analysis, showing a decrease of vent1 expression (n=3 replicates, P<0.001). (K-M) bmp4 expression. (K) Uninjected control embryo. (L) fezf2 mRNA overexpressing embryo. (M) qPCR analysis, showing a decrease in vent1 expression (n=3 replicates, P<0.01). (N) fezf2 mis-expression leads to nuclear accumulation of β-catenin. 250 pg of either nuclear β-gal (control) or fezf2 mRNA was injected at 1-2 cell stage and section made at stage 10, DAPI mask used to reveal nuclear content and the localisation of nuclear β-catenin after masking, showing increased nuclear enrichment of β-catenin in fezf2 mis-expressed embryos. Both grayscale and pseudo-colour images have been used to show the level of β-catenin presence in the nucleus. (a and a’) control; (b and b’) fezf2 injected embryos.
Arrowhead: blastopore lip. (O-P) Axis duplication assay. (O) Schematic representation of ventral blastomere injection. 250 pg of mRNA, together with nuclear β-gal mRNA as tracer, was injected into one of the ventral blastomere (arrowhead) at the 4-cell stage. Embryos were fixed at approximately stage 38 and stained with Red-gal. D: dorsal side. (P) Results of axis duplication assay. (a) Control embryo, nuclear β-gal mRNA injection only. (b) 250 pg fezf2 mRNA. (c) 250 pg β-catenin mRNA. (Q) Dual-luciferase assay on control FOPFlash plasmid containing mutated TCF-binding sites. pTK-renilla was used as endogenous control. (R) qPCR analysis on wnt1, wnt3a, and wnt8b in nuclear β-gal (control) or fezf2-injected neuralised animal cap explants aged to stage 15. n=3 replicates. * P<0.05. In all cases, error bars represent ±s. e. m. (K) Schematic representation of animal cap explant assay. mRNA at different combinations were injected at the 1-2 cell stage and allowed to develop until the mid-blastula stage (stage 8). Animal cap explants were excised at stage 8 and allowed to develop to stage 20, at which point they were collected for qPCR analysis.
**Figure S6 (related to Figure 3).** *fezf2*-regulated endogenous level of Wnt/β-catenin signalling governs forebrain neurogenesis in transgenic embryos. (A-C) Phenotypic effect of antimorphic Fezf2. (A) nuclear β-gal (control) mRNA, (B) *fezf2* mRNA, showing strongly dorsal-anteriorized (DAI 8-9) embryos. (C) VP16-*fezf2* mRNA, showing strongly ventralised (DAI 1-2) embryos. (D) GFP expression in the forebrain of embryos from different transgenic lines at day 7, top view. (a) NβT-GFP-*fezf2*-Katushka. Green: GFP; red: Katushka (inset). (b) NβT-GFP-*fezf2*-VP16-Fezf2. (c) NβT-GFP-*fezf2*-ΔN90βcatenin. (d) NβT-GFP-*fezf2*-ΔN51Tcf3. (e) NβT-GFP-*fezf2*-GSK3βS9A.
**Figure S7 (related to Figure 5).** Demonstration of ChIP-qPCR efficiency and Fezf2 binding site. (A) ChIP-qPCR result of FLAG-tagged FoxH1 using IgG (control) or anti-FLAG antibody, showing enrichment in the proximity of branchyury (xbra) promoter. (B) Schematics of the three highly conserved regions screened by ChIP-qPCR, highlighted areas have been screened using primers designed against each of the different regions.
**Figure S8 (related to Figure 6).** Fezf2 represses the activities of *lhx2* and *lhx9*. (A-B) Control experiments showing the expression of *lhx2* and *lhx9* in stage 12 animal cap
explants injected with p3hGR-VP16-Fezf2, either left untreated, or treated with either CHX or DEX alone. qPCR results of (A) *lhx2* and (B) *lhx9* are shown (*n*=3 replicates, \( P<0.001 \)). *rpl8* was used as an internal control. (C-D) Stage 20 animal cap explants neuralised by *chordin* mRNA expressed high level of *lhx2* and *lhx9*. qPCR results of (C) *lhx2* and (D) *lhx9* are shown (*n*=3 replicates, \( P<0.001 \) and \( P<0.05 \)). *rpl8* was used as an internal control. (E) Bar graph of the quantification and statistics of phenotypes from control or *fezf2* morphant groups regarding the expression of *lhx2* and *lhx9*. (F-G) Validation of *lhx2* i2e3 MO. (F) Validation by RT-PCR. M: marker. Lane 1-2: *rpl8*; 1: control MO; 2: *lhx2* MO. Lane 3-4: *lhx2*; Lane 3: control MO, Lane 4: *lhx2* MO. (G) Validation by qPCR. *rpl8* was used as an internal control in both cases. *n*=3 replicates, \( P<0.001 \). (H-I) Validation of *lhx9* e1i1 MO. (H) Validation by RT-PCR. M: marker. Lane 1-2: *rpl8*; 1: control MO; 2: *lhx9* MO. Lane 3-4: *lhx9*; Lane 3: control MO, Lane 4: *lhx9* MO. (I) Validation by qPCR. *rpl8* was used as an internal control in both cases. *n*=3 replicates, \( P<0.01 \). (J) Bar graph of the quantification and statistics of phenotypes from different morphant groups regarding *arx* expression. (K) Bar graph of the quantification and statistics of phenotypes from different morphant groups regarding *ngn1* expression. In all bar graphs, numbers above each bar represent counts of embryos examined in each group. Error bars represent ± s. e. m.
Table S1. Results of the axis branching assay.

Click here to Download Table S1

Table S2. Primers used in making constructs and qPCR analysis.

Click here to Download Table S2